The Mukherjee Cardiovascular Innovations Lab harnesses cutting-edge imaging techniques to explore cardiovascular manifestations and enhance the screening, early detection, and prediction of adverse clinical events across a broad range of autoimmune diseases.

Research in the Mark Liu Lab explores several areas of pulmonary and respiratory medicine. Our studies primarily deal with allergic inflammation, chronic obstructive pulmonary disease (COPD) and asthma, specifically immunologic responses to asthma. We have worked to develop a microfluidic device with integrated ratiometric oxygen sensors to enable long-term control and monitoring of both chronic and cyclical hypoxia. In addition, we conduct research on topics such as the use of magnetic resonance angiography in evaluating intracranial vascular lesions and tumors as well as treatment of osteoporosis by deep sea water through bone regeneration.

The Barouch Lab is focused on defining the peripheral cardiovascular effects of the adipocytokine leptin, which is a key to the understanding of obesity-related cardiovascular disease. Interestingly, many of the hormonal abnormalities seen in obesity are mimicked in heart failure. The research program will enhance the understanding of metabolic signaling in the heart, including the effects of leptin, exercise, sex hormones, and downstream signaling pathways on metabolism and cardiovascular function. The lab also is working to determine the precise role of the “metabolic” beta-3 adrenergic receptor (ß3AR) in the heart and define the extent of its protective effect in obesity and in heart failure, including its role in maintaining nitric oxide synthase (NOS) coupling. Ultimately, this work will enable the exploration of a possible therapeutic role of ß3AR agonists and re-coupling of NOS in preventing adverse ventricular remodeling in obesity and in heart failure. Lili Barouch, MD, is an associate professor of medicine in the Division of Cardiology and a member of the Advanced Heart Failure and Cardiac Transplantation group at the Johns Hopkins University School of Medicine.

Dr. Sozio’s research focuses on 1) Clinical research related to chronic kidney disease and end stage renal disease, and 2) Educational research in undergraduate and graduate medical education.

The Sozio lab pursues work related to stroke, cognitive impairment, manifestations of kidney disease, and systematic reviews on clinical topics, and collaborates on multiple projects with other key investigators. In particular, Dr. Sozio has been an active investigator in the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study, Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) Study, Chronic Renal Insufficiency Cohort (CRIC) Study, and work funded through the Agency for Healthcare Research and Quality (AHRQ) and Johns Hopkins Evidence-Based Practice Center. In addition, the Sozio lab performs studies at the UME and GME levels, investing in understanding learners’ mentorship, research, and transitional experiences.

Shelby Kutty, M.D., Ph.D., is an authority on cardiovascular imaging, including echocardiography, magnetic resonance imaging and computed tomography of congenital heart disease. His areas of academic interest have focused on myocardial function assessment, therapeutic ultrasound and cardiovascular outcomes. Kutty’s research includes developing new imaging technology applications such as a smartphone application that uses patients’ echocardiographic images to track their progress. His work gives pediatric cardiologists better ways to predict outcomes in their patients and provide the most effective and appropriate treatments.

Research in the Sharon Turban Lab focuses on the effects of sodium and potassium on blood pressure and on kidney function. We lead the Chronic Kidney Disease-Potassium (CKD-K) clinical trial, funded by American Heart Association, which examines the benefits and safety of two levels of potassium intake in patients with kidney disease. Other research includes the Chronic Renal Insufficiency Cohort (CRIC) study, which aims to improve the understanding of chronic kidney disease and related cardiovascular illness.

Research in the Rasika Mathias Lab focuses on the genetics of asthma in people of African ancestry. Our work led to the first genomewide association study of its kind in 2009. Currently, we are analyzing the whole-genome sequence of more than 1,000 people of African ancestry from the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA). CAAPA’s goal is to use whole-genome sequencing to expand our understanding of how genetic variants affect asthma risk in populations of African ancestry and to provide a public catalog of genetic variation for the scientific community. We’re also involved in the study of coronary artery disease though the GeneSTAR Program, which aims to identify mechanisms of atherogenic vascular diseases and attendant comorbidities.

Dr. Hua's research has centered on the development of novel MRI technologies for in vivo functional and physiological imaging in the brain, and the application of such methods for studies in healthy and diseased brains. These include the development of human and animal MRI methods to measure functional brain activities, cerebral perfusion and oxygen metabolism at high (3 Tesla) and ultra-high (7 Tesla and above) magnetic fields. He is particularly interested in novel MRI approaches to image small blood and lymphatic vessels in the brain. Collaborating with clinical investigators, these techniques have been applied 1) to detect functional, vascular and metabolic abnormalities in the brain in neurodegenerative diseases such as Huntingdon's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD) and mental disorders such as schizophrenia; and 2) to map brain functions and cerebrovascular reactivity for presurgical planning in patients with vascular malformations, brain tumors and epilepsy.

Research in the Jeffrey Dodd-o Lab aims to better understand the contributing factors of lung ischemia/reperfusion injuries and the role these injuries play in the lung dysfunction of patients soon after cardiopulmonary bypass surgery. We have created an ischemia/reperfusion model in a spontaneously breathing mouse that they use with an in situ mouse lung preparation to identify cardiopulmonary interactions that impact reperfusion-related lung injury. We are working to characterize the influence of atrial natriuretic peptide (ANP) on lung microvascular permeability.

The lab’s assets include three MRI systems available for pediatric studies, cardiac imaging processing, cardiovascular imaging and therapeutic ultrasound. A robust echocardiogram program conducts 10,000 transthoracic echocardiograms and 1,300 fetal echocardiograms per year, and maintains a database with 10 years of data.